Sarepta Therapeutics, Inc. (SRPT)
$
22.26
-0.56 (-2.52%)
Key metrics
Financial statements
Free cash flow per share
-3.8673
Market cap
2.2 Billion
Price to sales ratio
0.9264
Debt to equity
0.9470
Current ratio
2.9545
Income quality
0.9010
Average inventory
1 Billion
ROE
-0.2031
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for rare diseases. The diluted EPS is $2.34 accounting for potential share dilution. The financial data pertains to the fiscal year 2024 reflecting the overall performance of the company. The income before tax ratio is 0.14 which showcases the pre-tax margin and operational efficiency of Sarepta. Furthermore, the cost of revenue for the company is $319,099,000.00 highlighting its production and operational expenses. Despite these costs, the company earned an interest income of $71,767,000.00 showcasing its financial investments and ability to generate additional revenue streams. Sarepta offers the EXONDYS 51 injection and VYONDYS 53 for the treatment of Duchenne muscular dystrophy in patients with specific confirmed mutations in the dystrophin gene. The company is also progressing in developing AMONDYS 45, SRP-5051, SRP-9001, and SRP-9003, thereby solidifying its commitment to addressing rare genetic diseases through innovative therapies. Currently, the stock is reasonably priced at $17.43 appealing to a broad range of investors. This attractiveness is further supported by an average trading volume of 5,573,111.00 indicating moderate liquidity for potential and existing shareholders. With a mid-range market capitalization of $2,181,103,116.00 the company is a steady performer in its sector. It is a key player in the biotechnology industry, contributing significantly to the overall market landscape, while also driving innovation and growth in the healthcare sector. Through its collaborations with multiple organizations, Sarepta continues to enhance its research and development capabilities, positioning itself as a leader in genetic therapies and a vital contributor to advancements aimed at treating rare diseases.
Is Sarepta Therapeutics, Inc. (SRPT) a good investment?
Investing in Sarepta Therapeutics, Inc. (SRPT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Sarepta Therapeutics, Inc. (SRPT)'s stock forecast?
Analysts predict Sarepta Therapeutics, Inc. stock to fluctuate between $10.42 (low) and $131.31 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Sarepta Therapeutics, Inc.'s market capitalization?
As of 2025-12-05, Sarepta Therapeutics, Inc.'s market cap is $2,181,103,116, based on 97,983,069 outstanding shares.
How does Sarepta Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Sarepta Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Sarepta Therapeutics, Inc. (SRPT) stock?
To buy Sarepta Therapeutics, Inc. (SRPT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SRPT. Place an order (Market, Limit, etc.).
What is the best time to invest in Sarepta Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Sarepta Therapeutics, Inc. stock ever split?
Sarepta Therapeutics, Inc.'s last stock split was 1:6 on 2012-07-12.
How did Sarepta Therapeutics, Inc. perform in the last earnings report?
Revenue: $1,901,979,000 | EPS: $2.47 | Growth: -142.59%.
Where can I find Sarepta Therapeutics, Inc.'s investor relations reports?
Visit https://www.sarepta.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Sarepta Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Sarepta Therapeutics, Inc. stock?
All-time high: $173.25 (2024-06-21) | All-time low: $10.42 (2025-07-24).
What are the key trends affecting Sarepta Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
zacks.com
SRPT's stock jumps as its SRP-1003 study advances with a positive safety review and new dosing cohorts underway.
benzinga.com
The U.S. Food and Drug Administration (FDA) on Tuesday approved dosing in Sarepta Therapeutics Inc.'s (NASDAQ: SRPT) Cohort 8 of ENDEAVOR (Study 9001-103).
businesswire.com
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ARO-DM1, also called SRP-1003, an investigational RNA interference (RNAi) therapeutic for the treatment of type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy.
zacks.com
SRPT's Elevidys gets a sharply narrowed FDA label with new liver safety warnings that reshape how the gene therapy can be used.
benzinga.com
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock jumped on Friday after the FDA issued a new boxed warning for Elevidys. The updated approval follows recent reports of fatal liver injury in non-ambulatory pediatric patients who received the gene therapy.
businesswire.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an update to the prescribing information for ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for Duchenne muscular dystrophy (DMD). As previously disclosed, the ELEVIDYS label now includes several key updates, including: A boxed warning for the risk of acute serious liver injury (ALI) and acute liver failure (ALF).
reuters.com
The U.S. Food and Drug Administration said on Friday it approved new labeling for Sarepta Therapeutics' gene therapy Elevidys that includes its most serious safety warning and restricts use of the treatment to walking patients with Duchenne muscular dystrophy.
zacks.com
Sarepta's Q3 loss and the failure of its key DMD study sent shares tumbling, clouding hopes for its PMO therapies and gene therapy Elevidys.
seekingalpha.com
Sarepta Therapeutics, Inc. faces uncertainty after Elevidys' revenue decline and ESSENCE trial failure, leading to a 25% SRPT stock drop. SRPT's PMO franchise remains its cash engine, but regulatory reliance on real-world evidence and FDA unpredictability add risk to the investment thesis. Label contraction for Elevidys and margin pressures weigh on near-term outlook, with upside catalysts mostly expected in 2026 from RNA therapeutics data.
See all news
